Pear Therapeutics extends gain after LJ10 LLC disclosed stake. Pear recently closed its business combination with SPAC Thimble Point Acquisition. The combined company, Pear Therapeutics (PEAR), began trading on NASDAQ. The transaction was expected to generate about $175M in gross proceeds.
The rapidly emerging PDT category is building momentum with accelerating clinical validation, patient adoption, prescriber utilization, and payor reimbursement. This is a buy and hold! With this little float i will fly then!$Pear Therapeutics(PEAR)$
精彩评论